

AMENDMENTS TO THE SPECIFICATION

On page 7 of the specification, please amend the description of Figure 1 as follows:

Figure 1 shows the DNA sequence of IL-1 β 3'UTR (SEQ ID NO:28);

On page 7 of the specification, please amend the description of Figure 2 as follows:

Figure 2 shows the 30 bp fragment used as a mRNA instability sequence in Example 1 (SEQ ID NOs: 29 and 30);

On page 8 of the specification, please amend the description of Figure 9 as follows:

Figure 9 shows the cDNA construct derived from the Human APP 3'UTR[[.]] (SEQ ID NO:1);

On page 8 of the specification, please amend the description of Figure 10 as follows:

Figure 10 shows the cDNA construct derived from the Human bcl-2 α long 3'UTR (SEQ ID NO:2);

On page 8 of the specification, please amend the description of Figure 11 as follows:

Figure 11 shows the cDNA construct derived from the Human bcl-2 α short 3'UTR (SEQ ID NO:3);

On page 8 of the specification, please amend the description of Figure 12 as follows:

Figure 12 shows the cDNA construct derived from the Human c-myc 3'UTR (SEQ ID NO:4);

On page 8 of the specification, please amend the description of Figure 13 as follows:

Figure 13 shows the cDNA construct derived from the Human TNF α 3'UTR (SEQ ID NO:5);

On page 8 of the specification, please amend the description of Figure 14 as follows:

Figure 14 shows the cDNA construct derived from the Human IL-1 β 3'UTR (SEQ ID NO:6);

On page 8 of the specification, please amend the description of Figure 15 as follows:

Figure 15 shows the cDNA construct derived from the Human VEGF 3'UTR (SEQ ID NO:7);

On page 8 of the specification, please amend the description of Figure 16 as follows:

Figure 16 shows the cDNA construct derived from the Human VEGF hypoxia domain 3'UTR (SEQ ID NO:8); and

On page 41 of the specification, please amend the paragraph bridging the bottom of page 41 and the top of page 42 as follows:

Two unphosphorylated oligonucleotides, N/N-TK5P: **TGC***G***G***C***G***C***A***A***C***A***T***A***G***T***T***C***C***T***(SEQ ID NO: 31)** and N/N-TK3P: **A***A***C***A***T***A***T***G***T***T***G***C***G***C***G***C***A***A***G***G***(SEQ ID NO: 32)** were annealed and ligated into PflM1 linearized pGL2_Neo. The annealed oligonucleotides formed a small multiple cloning site containing the restriction enzyme sites for NotI (shown in bold and italics) and NdeI (shown in bold, italics and underline). It should be noted that this small multiple cloning site can be enlarged to contain additional unique restriction sites. The orientation of the NotI/ NdeI multiple cloning site of the resulting plasmid, pGL2NeoN/N, was verified by DNA sequencing.

On page 50 of the specification, please amend the first complete paragraph on the page as follows:

The resulting pTK-Hyg-SalI plasmid, was linearized with HindIII and dephosphorylated with calf intestinal phosphatase (CIP). Two primers, TKXF3 (5'-phos-AGCTGCTAG**CTCGAG**ATCTG) (SEQ ID NO: 26) and TKXR3 (5'-phos-AGCTCAGAT**CTCGAG**CTAGC) (SEQ ID NO: 27) were annealed and ligated into HindIII linearized pTK-Hyg/SalI (HindIII site located at 1037 of original pTK-Hyg vector). The resulting plasmid was identified as pTK-Hyg-SalI/XhoI.